无丙型肝炎病毒共感染的人pegivirus 2慢性感染
研究对注射吸毒者纵向血样用HPgV-2特异分子和血清学检测,发现既往或现症HCV感染者中HPgV-2感染率为11.2%(22/197),HCV阴性者为1.9%(4/205)。5例HPgV-2阳性者呈慢性感染,其中3例来自HCV阴性组,表明HPgV-2可在无HCV时建立慢性感染并复制。
要点
- HPgV-2感染主要与HCV感染相关,但在HCV阴性注射吸毒者中也可发生。
- HPgV-2可在无HCV共感染的情况下建立慢性感染(>6个月病毒血症)。
- HCV阴性者中HPgV-2感染率低于HCV阳性者(1.9% vs 11.2%)。
核心结论
- HPgV-2可在无HCV感染的情况下建立慢性感染并复制。
研究设计与样本
- 对注射吸毒者纵向收集的血样,采用HPgV-2特异性分子和血清学检测评估活动性与已消退的HPgV-2感染。
主要发现
- 既往或现症HCV感染的注射吸毒者中HPgV-2感染率为11.2%(22/197)。
- HCV阴性注射吸毒者中HPgV-2感染率为1.9%(4/205)。
- HPgV-2阳性者中5例为慢性感染(>6个月病毒血症,>3个时间点),其中2例来自HCV阳性组、3例来自HCV阴性组。
临床怎么用
- 对注射吸毒者进行HPgV-2检测时,不应仅局限于HCV感染者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most human pegivirus 2 (HPgV-2) infections are associated with past or current hepatitis C virus (HCV) infection. HPgV-2 is thought to be a bloodborne virus: higher prevalence of active infection has been found in populations with a history of parenteral exposure to viruses. We evaluated longitudinally collected blood samples obtained from injection drug users (IDUs) for active and resolved HPgV-2 infections using a combination of HPgV-2-specific molecular and serologic tests. We found evidence of HPgV-2 infection in 11.2% (22/197) of past or current HCV-infected IDUs, compared with 1.9% (4/205) of an HCV-negative IDU population. Testing of available longitudinal blood samples from HPgV-2-positive participants identified 5 with chronic infection (>6 months viremia in >3 timepoints); 2 were identified among the HCV-positive IDUs and 3 among the HCV-negative IDUs. Our findings indicate that HPgV-2 can establish chronic infection and replicate in the absence of HCV.
引用
- Coller KE, Bruce V, Cassidy M, et al. Chronic Human Pegivirus 2 without Hepatitis C Virus Co-infection. Emerg Infect Dis. 2020. PMID: 31961294. doi:10.3201/eid2602.190434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。